Leqembi Comes Home—but Alzheimer’s Treatment Does Not Become “Low-Monitoring”
On July 13, 2026, the FDA approved LEQEMBI IQLIK® (lecanemab-irmb) as a subcutaneous starting regimen for patients with early symptomatic Alzheimer’s disease.
This is more than a new formulation. It represents a meaningful shift in where disease-modifying Alzheimer’s treatment can occur.
Until now, patients beginning lecanemab generally had to travel to an infusion center every two weeks. The newly approved starting regimen is 500 mg once weekly, administered as two 250 mg autoinjector injections. After 18 months, patients may continue the starting regimen or transition to maintenance treatment, including a 360 mg weekly subcutaneous dose. FDA announcement
For patients and caregivers, this could mean fewer infusion-center visits, less travel, greater scheduling flexibility and—in areas with limited infusion capacity—better access to treatment.
But the most important message is this:
Moving drug administration into the home does not move Alzheimer’s treatment out of specialized medical care.
“At home” does not mean “first dose without supervision”
The phrase “at-home initiation” may create the impression that a patient can receive a prescription and begin injecting independently.
That is not what the label says.
Treatment must be initiated under the guidance and supervision of a healthcare provider. Before home administration, the clinician must provide direct guidance for at least two consecutive subcutaneous doses and determine that the patient or caregiver can:
Use the autoinjector correctly
Follow the weekly two-injection starting regimen
Recognize injection and hypersensitivity reactions
Respond appropriately if concerning symptoms occur
The clinician must also periodically reassess whether home administration remains appropriate. Current prescribing information
This distinction matters, particularly when the person receiving treatment already has cognitive impairment. In many cases, successful home treatment will depend as much on the reliability and understanding of the care partner as on the patient.
The injection is the simplest part of the treatment pathway
Before treatment begins, the diagnosis must be established carefully. Lecanemab is intended for patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease—not for nonspecific memory complaints, moderate or advanced dementia, or cognitive impairment without confirmed amyloid pathology.
Patients still require:
A clinical assessment confirming an appropriate disease stage
Confirmation of cerebral amyloid pathology
A recent baseline brain MRI
Review of microhemorrhages, superficial siderosis and other findings suggestive of cerebral amyloid angiopathy
APOE ε4 testing and a meaningful discussion of its implications
Medication review, particularly for anticoagulants and antithrombotic agents
A clear plan for recognizing and responding to possible amyloid-related imaging abnormalities, or ARIA
The current label calls for surveillance MRIs after one, two, three and six months of treatment, with additional imaging when symptoms suggest ARIA.
Home injection therefore removes an important logistical burden—but it does not remove the diagnostic, imaging or safety infrastructure surrounding treatment.
ARIA risk does not disappear when the infusion chair does
Lecanemab retains its boxed warning for ARIA, including ARIA-E, involving edema or effusion, and ARIA-H, involving microhemorrhage or superficial siderosis.
In the pivotal intravenous trial, radiographic ARIA occurred in 21% of lecanemab-treated patients, although many events were asymptomatic. Symptomatic ARIA occurred in 3%, and serious symptoms in 0.7%.
Risk was substantially higher among APOE ε4 homozygotes. In the trial, ARIA occurred in 45% of treated homozygotes, compared with 19% of heterozygotes and 13% of noncarriers. These numbers make APOE testing more than a laboratory checkbox: the result must inform a genuine shared decision about risk, expected benefit and the patient’s tolerance for uncertainty.
Anticoagulation also requires individualized judgment. It is not listed as an absolute FDA contraindication, but the label urges particular caution in patients who require anticoagulant therapy or have imaging findings suggestive of cerebral amyloid angiopathy.
Families must understand that new headache, confusion, visual disturbance, dizziness, gait difficulty, nausea, seizure or focal neurologic symptoms may require urgent assessment. Clinicians outside the treating center—especially emergency physicians—also need to know that ARIA can mimic ischemic stroke and may affect decisions concerning thrombolytic therapy.
What evidence supports the subcutaneous regimen?
Another point deserves clear communication.
The subcutaneous starting regimen was not evaluated in a separate, large, randomized clinical-outcomes trial comparable to the pivotal intravenous Clarity AD study.
Instead, the FDA relied on the clinical efficacy established with intravenous lecanemab, together with pharmacokinetic modeling showing comparable exposure and predicted similar amyloid reduction with 500 mg weekly subcutaneous dosing. The safety assessment was supported by open-label subcutaneous studies, including data from 72 patients receiving subcutaneous lecanemab as their starting treatment.
That does not invalidate the approval. Pharmacokinetic and biomarker bridging are established regulatory approaches. But patients and clinicians should understand precisely what has—and has not—been demonstrated.
The real opportunity: redesigning the care pathway
If implemented well, subcutaneous initiation could redistribute resources more intelligently.
Infusion capacity could be preserved for patients who prefer or require intravenous administration. Rural and mobility-limited patients may face fewer trips. Caregivers may lose fewer workdays. Treatment may become feasible for some patients who previously lived too far from a qualified infusion center.
At the same time, healthcare systems will need reliable processes for:
Initial hands-on training
Specialty-pharmacy coordination and medication storage
Adherence tracking
Timely surveillance MRI scheduling and review
After-hours symptom triage
Communication with emergency departments
Documentation of APOE counseling and shared decision-making
Rapid treatment interruption when ARIA is suspected
The burden is therefore not eliminated; it is redistributed. Some of it moves from infusion nurses and facilities to patients, caregivers, specialty pharmacies and outpatient neurology teams.
That transition must be designed deliberately.
My takeaway
This approval is an important advance in access and patient choice. For the right patient, supported by a capable caregiver and an experienced clinical team, at-home subcutaneous lecanemab may substantially reduce the practical burden of disease-modifying treatment.
But convenience should never be confused with simplicity.
The site of administration may be the home. The treatment remains a high-complexity neurologic intervention.
Our task is not merely to make anti-amyloid therapy easier to inject. It is to build care systems that make it safer, more equitable and more understandable—while preserving the careful patient selection and monitoring that these therapies demand.
LEQEMBI IQLIK initiation dosing is expected to become commercially available in the United States in late August 2026 through specialty pharmacies. Eisai and Biogen announcement
This article is for professional and educational discussion and is not individualized medical advice.
Bibliography
U.S. Food and Drug Administration. FDA Approves First At-Home Starting Dose for Alzheimer’s Disease Treatment. July 13, 2026.
Eisai Inc. LEQEMBI® (lecanemab-irmb): Full Prescribing Information. Revised July 2026.
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023;388(1):9-21. doi:10.1056/NEJMoa2212948.
Eisai Inc, Biogen Inc. FDA Approves LEQEMBI IQLIK® Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease. July 13, 2026.
About the Author
Myrna Cardiel, MD, MSCP, DipABLM, DABOM, is a board-certified neurologist and former Clinical Professor of Neurology at NYU Langone Health, with more than 20 years of clinical experience. Her work focuses on memory and cognitive concerns, women’s neurological health, midlife brain concerns, migraine, headache disorders, and the effects of hormonal and metabolic health on brain function.
Dr. Cardiel is the founder of Cardiel Precision Brain Health, a private, limited-volume neurology practice near Grand Central in Manhattan. The practice provides extended consultations, individualized diagnostic planning, longitudinal care, and close coordination with referring clinicians for adults seeking thoughtful care for migraine, cognitive concerns, and long-term brain health.
